| Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in accelerated phase. | |
| | |
MedLine Citation:
|
PMID: 21252092 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib for chronic myelogenous leukemia (CML) in accelerated phase (AP) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n=87) versus allo-HSCT (n=45) for AP CML. A multivariate analysis of the total population revealed that CML duration > 12 months, hemoglobin < 100 g/L and peripheral blood blasts > 5% were independent adverse prognostic factors for both overall survival (OS) and progression-free survival (PFS). Both treatments resulted in similar survival in low-risk (no factor) patients, with six-year event-free survival (EFS), OS and PFS rates of more than 80.0%. Intermediate-risk (any factor) patients showed no difference in EFS and OS, but six-year PFS rates were 55.7% vs. 92.9% (P=0.047) with imatinib versus allo-HSCT. Among high-risk (at least two factors) patients, imatinib was by far inferior to allo-HSCT, with five-year EFS, OS and PFS rates of 9.3% vs. 66.7% (P=0.034), 17.7% vs. 100% (P=0.008) and 18.8% vs. 100% (P=0.006), respectively. We conclude that allo-HSCT, compared to imatinib, confers significant survival advantages for high- and intermediate-risk patients with AP CML; however, the outcomes of the two therapies are equally good in low-risk patients. All trials were registered with www.chictr.org as CHiCHTR-TNC-10000955. |
| | |
Authors:
|
Qian Jiang; Lan-Ping Xu; Dai-Hong Liu; Kai-Yan Liu; Shan-Shan Chen; Bin Jiang; Hao Jiang; Huan Chen; Yu-Hong Chen; Wei Han; Xiao-Hui Zhang; Yu Wang; Ya-Zhen Qin; Yan-Rong Liu; Yue-Yun Lai; Xiao-Jun Huang |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-1-20 |
Journal Detail:
|
Title: Blood Volume: - ISSN: 1528-0020 ISO Abbreviation: - Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-1-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7603509 Medline TA: Blood Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophag...
Next Document: Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppres...